Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.64
+0.19000.35%
Post-market: 55.250.6100+1.12%17:04 EDT
Volume:2.25M
Turnover:122.44M
Market Cap:13.54B
PE:17.18
High:55.02
Open:54.10
Low:53.43
Close:54.45
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.22
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.34
PE(LYR):19.65

Loading ...

Exelixis to webcast investor conference fireside chats in June

Reuters
·
May 28

Exelixis EVP Commercial Patrick J. Haley sells 32,110 shares for $1.6 million

Reuters
·
May 23

Exelixis to present Cabometyx, zanzalintinib studies at ASCO annual meeting

Reuters
·
May 22

How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration

Simply Wall St.
·
May 21

Top Exelixis Executive Cashes In on Major Stock Sale

TIPRANKS
·
May 20

Exelixis EVP, CFO Christopher Senner disposes 75,793 shares for $3.78 million

Reuters
·
May 20

Exelixis SVP, General Counsel Brenda Hefti disposes 13,036 shares worth $662,202.55

Reuters
·
May 20

Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial

MT Newswires Live
·
May 19

Exelixis partners with Merck on phase 3 colorectal cancer trial combining zanzalintinib, Keytruda Qlex

Reuters
·
May 19

Exelixis Inc - Expects to Initiate Stellar-316 in Mid-2026

THOMSON REUTERS
·
May 19

Exelixis Inc - Merck to Supply Keytruda Qlex for Stellar-316 Trial

THOMSON REUTERS
·
May 19

Exelixis Announces Clinical Development Collaboration With Merck for Phase 3 Stellar-316 Pivotal Trial for Patients With Colorectal Cancer

THOMSON REUTERS
·
May 19

Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion

TIPRANKS
·
May 19

Exelixis director Mary C. Beckerle disposes 7,712 shares for $373,646.4

Reuters
·
May 09

Exelixis Director Maria C. Freire disposes 20,634 shares for $949,164

Reuters
·
May 09

Exelixis director George Poste disposes 60,000 shares for $2.74 million

Reuters
·
May 09

Exelixis to webcast investor conference fireside chats in May

Reuters
·
May 08

Exelixis Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 07

Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives

Simply Wall St.
·
May 07

Exelixis, Inc. : H.c. Wainwright Raises Target Price to $56 From $54

THOMSON REUTERS
·
May 07